Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD - Seite 2

Unparalleled AID abilities

With robust clinical evidence and strong partner relationships, Dexcom’s pioneering leadership and capabilities within connected systems remains unparalleled. Of particular significance within AID systems, the clinically meaningful health outcomes resulting from use of both the Tandem t:slim X2 insulin pump with Control-IQ technology and Insulet Omnipod 5 are only proven when powered by Dexcom CGM. Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024. Data from the longest prospective follow-up study to date of a cohort with established Type 1 diabetes¹, using the Insulet Omnipod 5 automated insulin delivery system with Dexcom G6, showed that long-term use of the AID system could safely maintain improvements in glycaemic outcomes for up to two years. Perhaps most significantly, despite the long duration of the study, event rates for severe hypoglycaemia and diabetic ketoacidosis remained low at 2.04 and 0.24 events per 100 person-years.

Furthermore, real-world evidence from almost 3,000 people using a Tandem Control-IQ AID system, powered by Dexcom CGM, demonstrated lower rates for both severe hypoglycaemia and diabetic ketoacidosis over 12 months compared to historic rates². Concurrent with these lower rates, on average adult participants spent more than 70% CGM time in range, while paediatric participants achieved 60% CGM time in range.

In December, Dexcom and Tandem announced the connection of Dexcom G7 to Tandem’s t:slim X2 insulin pump software in the USA, swiftly followed by a roll out in markets across Europe, and in both South Africa and New Zealand. The announcement marked a powerful alliance combining Dexcom’s best-in-class G7 sensor with Tandem’s most widely available pump system.

Dexcom also announced the availability, in the USA, of Dexcom G6 with Tandem Mobi, the world’s smallest, durable automated insulin delivery system⁺⁺. Integration with Dexcom G7 will quickly follow in the USA in the second quarter of this year.

Exceptionally effective CGM for all types of diabetes

As demonstrated in multiple symposia and presentations at ATTD this year, clinical evidence continues to build demonstrating the effectiveness of Dexcom CGM use amongst people with all types of diabetes. Of particular note, Dexcom announced a first-of-its-kind study directly linking the benefits of CGM with a reduction in mortality for people treating Type 1 or Type 2 diabetes with insulin^‡3. These results indicate use of CGM may have broad-based benefits that extend beyond glucose lowering in patients with diabetes on insulin.